Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed chronic genotype 1 or 3 HCV infection~* HCV treatment-naive~* Individuals will have cirrhosis status assessment; liver biopsy may be required.~* Screening laboratory values within predefined thresholds~* Use of two effective contraception methods if female of childbearing potential or sexually active male~Exclusion Criteria:~* Pregnant or nursing female or male with pregnant female partner~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~* Contraindication to ribavirin therapy~* Excessive alcohol ingestion as defined by protocol~* History of solid organ transplantation~* Current or prior history of clinical hepatic decompensation~* History of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment, or compliance with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF+RBV 16 Weeks (Type: EXPERIMENTAL): SOF+RBV for 16 weeks
- SOF+RBV 24 Weeks (Type: EXPERIMENTAL): SOF+RBV for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).